Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

Summary

This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (progressive). Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals tumor cells to multiply. This may help keep tumor cells from growing and may kill them. Giving erdafitinib may help to slow the growth of, or to shrink, tumor cells in patients with recurrent or progressive IDH-wild type gliomas with FGFR-TACC gene fusion.

Timeline

Start

2024-01-04

Primary completion

2026-10-23

Completion

2026-10-23

Publications

• Alshiehk Nasany R, de la Fuente MI. Molecularly driven therapies in the treatment of primary brain tumors. Adv Cancer Res. 2025;166:183-201. doi: 10.1016/bs.acr.2025.05.005. Epub 2025 May 27.

Drugs

Indications